Aya Kajihama

Aya Kajihama

Auto-generated profile, based on publicly available information

Aya Kajihama

Department of Pediatrics, Asahikawa Medical University, Asahikawa, Japan

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2008 in Epilepsy Research
Verified
Journal Article
Open access
STSatoru Takahashi
Satoru Takahashi
JOJunko Ohinata
Junko Ohinata
NSNao Suzuki
Nao Suzuki
SASatoshi Amamiya
Satoshi Amamiya
AKAya Kajihama
Aya Kajihama
HTHajime Tanaka
Hajime Tanaka
Glucose transporter 1 (GLUT1) deficiency syndrome is caused by a deficit in glucose transport to the brain during the pre- and postnatal periods. Here, we report two cases of GLUT1 deficiency syndrome diagnosed on the basis of clinical features, reduced GLUT1 activities, and mutations in the GLUT1 gene. Patient 1 had a novel heterozygous 1bp insertion in exon 7 that resulted in a shift of the reading frame and the introduction of a premature stop codon at amino acid position 380. His clinical phenotype appeared to be more severe than that of Patient 2 who had a missense mutation in exon 8 resulting in an arginine-to-tryptophan substitution at amino acid position 333. Patient 1 had no meaningful words and could not walk unassisted, while Patient 2 could speak and walk unassisted. Both the patients developed seizures of various types that have been successfully treated with zonisamide. Although several antiepileptic drugs, including barbiturates, diazepam, chloralhydrate, and valproic acid, have been shown to inhibit GLUT1 function, the present study demonstrated no inhibitory effect of zonisamide on GLUT1-mediated glucose transport. Our data suggested that zonisamide might be preferable if add-on anticonvulsant therapy is required to control the seizures in patients with this disorder.

14 July 2016 in Pediatrics International
Verified
Journal Article
Closed access
KNKouichi Nakau
Kouichi Nakau
MSMasaya Sugimoto
Masaya Sugimoto
HOHideharu Oka
Hideharu Oka
AKAya Kajihama
Aya Kajihama
JMJun Maeda
Jun Maeda
HAHiroshi Azuma
Hiroshi Azuma

1 January 2018 in Korean Circulation Journal
Verified
Journal Article
Open access
HOHideharu Oka
Hideharu Oka
KNKouichi Nakau
Kouichi Nakau
AKAya Kajihama
Aya Kajihama
HAHiroshi Azuma
Hiroshi Azuma
Oka H, et al. Korean Circ J. 2016 Sep;48:e62. https://doi.org/10.4070/kcj.2017.0017


1 January 2017 in Pediatric Cardiology and Cardiac Surgery
Verified
Journal Article
Closed access
HOHideharu Oka
Hideharu Oka
MSMasaya Sugimoto
Masaya Sugimoto
AKAya Kajihama
Aya Kajihama
KNKouichi Nakau
Kouichi Nakau
HMHiromi Manabe
Hiromi Manabe
HAHiroshi Azuma
Hiroshi Azuma

25 November 2018 in Case Reports in Cardiology
Verified
Journal Article
Open access
PDF file
HOHideharu Oka
Hideharu Oka
KNKouichi Nakau
Kouichi Nakau
AKAya Kajihama
Aya Kajihama
MSMasaya Sugimoto
Masaya Sugimoto
HAHiroshi Azuma
Hiroshi Azuma
Asplenia syndrome is frequently complicated by a total anomalous pulmonary venous connection. Pulmonary venous obstruction, following total anomalous pulmonary venous connection surgery, is one of the risk factors for morbidity and mortality. In some patients, the pulmonary vasculature is abnormal even in the absence of clinical evidence of pulmonary venous obstruction. We hypothesized that a change in the pulmonary hemodynamics could indicate the abnormality of pulmonary vein in a patient with asplenia, single right ventricle, and total anomalous pulmonary venous connection, following Fontan procedure. Here, we present a case of asplenia, single right ventricle, total anomalous pulmonary venous connection, and right pulmonary venous obstruction in which evidence of a potential left pulmonary venous obstruction was obtained following the administration of inhaled nitric oxide and oxygen.